Monitoring or toxicity
This summary uses the identified dated label. Verify the current label for this presentation before applying the regimen.
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding The inhaled regimen requires no renal dose change. At CrCl below 60 mL/min, monitor more closely for anticholinergic effects from tiotropium. Limits and monitoring Confirm the device and ingredients. Review urinary retention, glaucoma symptoms and other anticholinergic medicines. Review 1 product or source caution
Verify the current prescribing information for this presentation.
DailyMed SPL version 3, posted May 18, 2020 | Selected sections checked 2026-11-07. Independent clinical review pending.
Monitoring or toxicity
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding The inhaled regimen requires no renal dose change. At CrCl below 60 mL/min, monitor more closely for anticholinergic effects from tiotropium. Limits and monitoring Confirm the device and ingredients. Review urinary retention, glaucoma symptoms and other anticholinergic medicines. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 16, posted Aug 19, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Monitoring or toxicity
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding The inhaled regimen requires no renal dose change. At CrCl below 60 mL/min, monitor more closely for anticholinergic effects from tiotropium. Limits and monitoring Confirm the device and ingredients. Review urinary retention, glaucoma symptoms and other anticholinergic medicines. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 16, posted Jul 16, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.
Pharmacokinetics only
Renal measure Cockcroft-Gault CrCl, mL/min Renal action or finding The exposure analysis found no clinically important differences with mild or moderate impairment at Cockcroft-Gault CrCl 30 to below 90 mL/min. Limits and monitoring The result does not establish dosing in severe impairment or dialysis. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 11, posted Oct 26, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
No adjustment within stated limits
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding No renal dose change is required in mild or moderate impairment. Severe impairment has not been studied. Limits and monitoring Choose IV or subcutaneous dosing according to the indication and product presentation. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 53, posted Dec 19, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.
No adjustment within stated limits
This summary uses the identified dated label. Verify the current label for this presentation before applying the regimen.
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding The label permits usual dosing in mild or moderate renal impairment and advises caution in severe impairment. Limits and monitoring Follow the separate liver safety and monitoring requirements for tolcapone. Review 1 product or source caution
Verify the current prescribing information for this presentation.
DailyMed SPL version 13, posted Jan 05, 2021 | Selected sections checked 2026-11-07. Independent clinical review pending.
Dose or interval change
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding For significant renal impairment the immediate-release tolterodine regimen is 1 mg twice daily. Limits and monitoring Verify immediate-release tablets. The ER capsule has different dosing instructions. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 5, posted Feb 03, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.
Restriction or avoidance
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding CrCl below 10 mL/min is an unstudied range in which tolvaptan's sodium effect is likely lost. The label recommends against use there. Limits and monitoring Anuria is a contraindication. Apply the hyponatremia product's hospital initiation and sodium-monitoring instructions. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 23, posted Jun 01, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Dose or interval change
Renal measure CrCl normalized to 1.73 m2, mL/min/1.73 m2 Renal action or finding When indexed CrCl is below 70 mL/min/1.73 m2, use half the usual adult dose for the indication. Limits and monitoring Hemodialysis may require a supplement based on session duration, dialysis clearance, and residual kidney function. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 31, posted Oct 06, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Dose or interval change
Renal measure CrCl normalized to 1.73 m2, mL/min/1.73 m2 Renal action or finding At CrCl below 70 mL/min/1.73 m2 use half the usual adult extended-release topiramate dose for the indication. Limits and monitoring Hemodialysis can remove topiramate. Consult the dialysis section for session-specific considerations. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 31, posted Oct 06, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
No adjustment within stated limits
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Renal impairment does not require a treprostinil dose reduction for this presentation. Limits and monitoring Verify route, dose units and delivery system. Inhaled powder and continuous infusion have separate dosing regimens. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 35, posted Jul 20, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
No adjustment within stated limits
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Renal impairment does not require a treprostinil dose reduction for this presentation. Limits and monitoring Verify route, dose units and delivery system. Inhaled powder and continuous infusion have separate dosing regimens. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 14, posted Nov 26, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.
Return to top Find another drug
